Knowledge Center

With 44,000+ oncology professionals in attendance, ASCO 2026 may have been the most consequential in recent years. From a standing ovation for pancreatic cancer to the first positive sarcoma trial in history, here's everything that mattered at Chicago's McCormick Place this week.

‍

Real-time clinical trials are here. Medable's continuous trial management platform gives sponsors the evidence generation, agentic AI, and regulatory-ready infrastructure to run clinical programs at the speed the FDA now expects.

Oncology has never been in a better scientific position. Precision medicines, adaptive study designs, and biomarker-driven cohorts have opened up treatment possibilities that simply did not exist ten years ago. But the complexity of running these trials has grown at much the same pace as the science itself, and that gap between scientific ambition and operational capability is where many programmes quietly struggle.

For sponsors building oncology portfolios, and for the CROs executing them, the operational challenge is no longer a peripheral concern. Getting it right comes down to three things: being consistent enough to build efficiently, agile enough to adapt when the science changes, and scalable enough to manage a growing portfolio without the overhead growing at the same rate.

Medable has worked with sponsors and CROs across many global oncology programmes, spanning thousands of sites and participants. That experience has given us a clear picture of what separates programmes that move well from those that get stuck.

‍

Learn how a a top-10 global pharmaceutical company partnered with Medable to rapidly expand the number of oncology trials it could concurrently conduct.

‍

Discover how AI-enabled eCOA and agentic workflows reduce clinical trial startup time, translation cycles, and meeting overhead—cutting eCOA build timelines from 16–20 weeks to under 8 weeks.

Learn how Medable enabled a top-5 pharma to scale vaccine mega-trials with near-100% enrollment, real-time safety data, and >90% diary compliance.

‍

Deployment of remote and virtual clinical trial methods and technologies, referred to collectively as decentralized clinical trials (DCTs), represents a profound shift in clinical trial practice. To our knowledge, a comprehensive assessment of the financial net benefits of DCTs has not been conducted

Research looking at mobile apps and how they may provide a meaningful access point for all stakeholders for symptom management.

Artificial intelligence is reshaping clinical trial operations in 2026. Sponsors and CROs are no longer evaluating standalone tools. They are choosing platforms that can connect with existing systems, automate complex workflows, and scale without disrupting ongoing studies. This guide breaks down the vendors best positioned to integrate with the clinical trial infrastructure you already have.

‍

Artificial Intelligence is rapidly transforming clinical research. From patient recruitment and protocol design to medical writing and data review, AI-powered solutions are becoming embedded across the clinical development lifecycle. More recently, the emergence of Agentic AI (systems capable of planning, reasoning, and executing multi-step workflows with varying degrees of autonomy) has generated significant excitement throughout the industry.

However, not all AI solutions are created equal. While many vendors promise dramatic improvements in efficiency and productivity, clinical trial organizations operate in one of the most highly regulated environments in the world. Success depends not only on technical performance but also on compliance, validation, governance, security, and trust.

As sponsors, CROs, and technology teams evaluate potential AI partners, they need a framework that extends beyond traditional software procurement criteria. The following considerations can help organizations assess both AI and Agentic AI vendors and identify solutions that are truly ready for clinical research.

‍

Medable is a Palo Alto-based platform that has positioned itself as a leader specifically in decentralized clinical trials (DCT), eCOA, and — most recently — agentic AI. It has been deployed in nearly 400 trials across 70 countries and 120 languages, serving more than one million patients globally, and has been recognized as a Leader in eCOA by Everest Group.

‍